Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion ProteinsDana S. Neel, Trever G. Bivona, Golzar Hemmati et al.|Cancer Research|2018Cited by 98
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi‐Long Wu, Tae Min Kim, Valentina Guarneri et al.|The Lancet Oncology|2024Cited by 98